Pharsight

Ortho Mcneil Janssen patents expiration

1. Viadur patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5985305 ORTHO MCNEIL JANSSEN Sustained delivery of an active agent using an implantable system
Jan, 2017

(7 years ago)

US6156331 ORTHO MCNEIL JANSSEN Sustained delivery of an active agent using an implantable system
Jan, 2017

(7 years ago)

US5728396 ORTHO MCNEIL JANSSEN Sustained delivery of leuprolide using an implantable system
Jan, 2017

(7 years ago)

US6395292 ORTHO MCNEIL JANSSEN Sustained delivery of an active agent using an implantable system
Jan, 2017

(7 years ago)

US6132420 ORTHO MCNEIL JANSSEN Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
Jan, 2017

(7 years ago)

US6235712 ORTHO MCNEIL JANSSEN Non-aqueous polar aprotic peptide formulations
Jun, 2017

(6 years ago)

US5932547 ORTHO MCNEIL JANSSEN Non-aqueous polar aprotic peptide formulations
Jun, 2017

(6 years ago)

US6124261 ORTHO MCNEIL JANSSEN Non-aqueous polar aprotic peptide formulations
Jun, 2017

(6 years ago)

US6113938 ORTHO MCNEIL JANSSEN Beneficial agent delivery system with membrane plug and method for controlling delivery of beneficial agents
Jul, 2018

(5 years ago)

US6375978 ORTHO MCNEIL JANSSEN Rate controlling membranes for controlled drug delivery devices
Dec, 2018

(5 years ago)

Drugs and Companies using LEUPROLIDE ACETATE ingredient

Market Authorisation Date: 03 March, 2000

Treatment: Method of treating a subject suffering from prostate cancer

Dosage: IMPLANT;IMPLANTATION

More Information on Dosage

VIADUR family patents

Family Patents